

Första intrycket Elicera Therapeutics, kv3 2025: CARMA-studien fortskrider, uppdatering om ELC- 100 väntar

Carlsquare Equity Research har publicerat en kommentar till rapporten för kv3 2025.

[Läs hela kommentaren här.](#)

Om Carlsquare

Carlsquare is a global research firm and financial advisor focusing on M&A, Equity Research and Growth Equity. Carlsquare has 170 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience in the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. [Read more](#)

www.carlsquare.com

Kontakter

MARKUS AUGUSTSSON

Head of Equity Research

markus.augustsson@carlsquare.com

+46 (0)76 235 03 20

NIKLAS ELMHAMMER

Senior Equity Analyst

niklas.elmhammer@carlsquare.com

+46 (0)70 898 39 59

Bifogade filer

[Första intrycket Elicera Therapeutics, kv3 2025: CARMA-studien fortskrider, uppdatering om ELC-100 väntar](#)